EP Patent

EP1126841A1 — Method of treating migraines and pharmaceutical compositions

Assigned to Merck and Co Inc · Expires 2001-08-29 · 25y expired

What this patent protects

A combination of a 5HT<SUB>1B/1D </SUB>agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

USPTO Abstract

A combination of a 5HT<SUB>1B/1D </SUB>agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

Drugs covered by this patent

Patent Metadata

Patent number: EP1126841A1
Jurisdiction: EP
Classification: —
Expires: 2001-08-29
Drug substance claim: No
Drug product claim: No
Assignee: Merck and Co Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.